StemCells Inc (STEM) Thursday announced that it has completed the enrolment as well as transplantation for the first patient in its Phase I/II clinical trial in dry age-related macular degeneration, or AMD.
The company, engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery, stated that the trial is designed to evaluate the safety and preliminary efficacy of its proprietary HuCNS-SC product candidate as a treatment for dry AMD, and the patient was transplanted with the cells yesterday at the Retina Foundation of the Southwest (RFSW) in Dallas, Texas, one of the leading independent vision research centers in the United States.
"This trial signifies an exciting extension of our on-going clinical research with neural stem cells from disorders of the brain and spinal cord to now include the eye," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.